ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main f...
Após breves considerações a respeito da evolução clínica e diagnóstico na esclerose múltipla, os mem...
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system character...
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the releas...
Em razão dos avanços no conhecimento da esclerose múltipla (EM), dos novos critérios diagnósticos e ...
O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e ...
Recent changes to the diagnostic criteria for multiple sclerosis (MS) and new medications have had a...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years,...
O tratamento de pacientes com esclerose múltipla (EM) com imunomoduladores e, mais recentemente, com...
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying tre...
Objective. To provide recommendations on the use of disease-modifying agents in the management of mu...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Após breves considerações a respeito da evolução clínica e diagnóstico na esclerose múltipla, os mem...
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system character...
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective...
ABSTRACT Multiple sclerosis has become an ever-increasing challenge to neurologists. With the releas...
Em razão dos avanços no conhecimento da esclerose múltipla (EM), dos novos critérios diagnósticos e ...
O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e ...
Recent changes to the diagnostic criteria for multiple sclerosis (MS) and new medications have had a...
With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming incr...
Prodigious progress in the treatment of multiple sclerosis (MS) has occurred over the last 20 years,...
O tratamento de pacientes com esclerose múltipla (EM) com imunomoduladores e, mais recentemente, com...
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying tre...
Objective. To provide recommendations on the use of disease-modifying agents in the management of mu...
Objective : The prevalence of multiple sclerosis (MS) in Latin America varies across different studi...
Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studie...
Após breves considerações a respeito da evolução clínica e diagnóstico na esclerose múltipla, os mem...
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system character...
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis...